Boehringer Ingelheim and Bridge Biotherapeutics Inc. have entered a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877, for patients with fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis (IPF). BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.    Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with ...